Sexual absorption of vaginal progesterone: a randomized control trial

Abstract

Objective. To determine if sexual intercourse reduces absorption of vaginal progesterone gel in women and to determine if progesterone is absorbed by the male during intercourse. Study Design. Prospective, randomized, cross over, controlled study of 20 reproductive-aged women and their male sexual partners randomized to receive vaginal progesterone gel (Crinone 8% gel, Actavis Inc., USA) or placebo cream. Serum progesterone for both male and female partners were measured 10 hours after intercourse. One week later, subjects were crossed over to receive the opposite formulation. In the third week, women used progesterone gel at night and abstained from intercourse. Results. Serum progesterone was significantly reduced with vaginal progesterone gel + intercourse compared with vaginal progesterone gel + abstinence (P = 0.0075). Men absorbed significant progesterone during intercourse with a female partner using vaginal progesterone gel compared to placebo (P = 0.0008). Conclusion(s). Vaginal progesterone gel is reduced in women after intercourse which may decrease drug efficacy during luteal phase support. Because men absorb low levels of progesterone during intercourse, exposure could cause adverse effects such as decreased libido. This study is registered under Clinical Trial number NCT01959464.

Figures

Figure 1

Study methods.

Figure 2

Distribution of female serum progesterone by treatment group. Crinone and abstinence group: maximum 11.9, minimum 3.5, and average 7.042. Crinone and intercourse group: maximum 10.7, minimum 0.9, and average 4.021. Placebo and intercourse group: maximum 2.1, minimum 0.2, and average 0.842.

Figure 3

Distribution of male serum progesterone by treatment group. Crinone group: maximum 1.8, minimum 0.2, and average 0.853. Placebo group: maximum 1, minimum 0.3, and average 0.584.